1
|
Ali N, Rezvani HR, Motei D, Suleman S, Mahfouf W, Marty I, Ronkainen VP, Vainio SJ. Trisk 95 as a novel skin mirror for normal and diabetic systemic glucose level. Sci Rep 2020; 10:12246. [PMID: 32699238 PMCID: PMC7376074 DOI: 10.1038/s41598-020-68972-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Accepted: 07/03/2020] [Indexed: 11/21/2022] Open
Abstract
Developing trustworthy, cost effective, minimally or non-invasive glucose sensing strategies is of great need for diabetic patients. In this study, we used an experimental type I diabetic mouse model to examine whether the skin would provide novel means for identifying biomarkers associated with blood glucose level. We first showed that skin glucose levels are rapidly influenced by blood glucose concentrations. We then conducted a proteomic screen of murine skin using an experimental in vivo model of type I diabetes and wild-type controls. Among the proteins that increased expression in response to high blood glucose, Trisk 95 expression was significantly induced independently of insulin signalling. A luciferase reporter assay demonstrated that the induction of Trisk 95 expression occurs at a transcriptional level and is associated with a marked elevation in the Fluo-4AM signal, suggesting a role for intracellular calcium changes in the signalling cascade. Strikingly, these changes lead concurrently to fragmentation of the mitochondria. Moreover, Trisk 95 knockout abolishes both the calcium flux and the mitochondrial phenotype changes indicating dependency of glucose flux in the skin on Trisk 95 function. The data demonstrate that the skin reacts robustly to systemic blood changes, and that Trisk 95 is a promising biomarker for a glucose monitoring assembly.
Collapse
Affiliation(s)
- Nsrein Ali
- Laboratory of Developmental Biology, Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, Aapistie 5A, 90220, Oulu, Finland. .,Infotech Oulu, University of Oulu, 90220, Oulu, Finland.
| | - Hamid Reza Rezvani
- Inserm, BMGIC, UMR 1035, University of Bordeaux, Bordeaux, France.,Centre de Référence pour les Maladies Rares de la Peau, CHU de Bordeaux, Bordeaux, France
| | - Diana Motei
- Laboratory of Developmental Biology, Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, Aapistie 5A, 90220, Oulu, Finland
| | - Sufyan Suleman
- Laboratory of Developmental Biology, Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, Aapistie 5A, 90220, Oulu, Finland
| | - Walid Mahfouf
- Inserm, BMGIC, UMR 1035, University of Bordeaux, Bordeaux, France
| | - Isabelle Marty
- Inserm U1216, Grenoble Institut des Neurosciences, University Grenoble, La Tronche, France
| | | | - Seppo J Vainio
- Laboratory of Developmental Biology, Faculty of Biochemistry and Molecular Medicine, Biocenter Oulu, University of Oulu, Aapistie 5A, 90220, Oulu, Finland.,Infotech Oulu, University of Oulu, 90220, Oulu, Finland.,Borealis Biobank of Northern Finland, Oulu University Hospital, Oulu, Finland
| |
Collapse
|